Follow-up Study of Individuals with Autoantibodies Against Ro/SSA and La/SSB
NCT06594861 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2024-09-19
Summary
In this study, individuals with autoantibodies against Ro/SSA and La/SSB will be followed with regard to clinical manifestations and immunological parameters to identify immunological changes, environmental factors, and early clinical symptoms that characterize the progression from serological autoreactivity to clinically manifest disease.
Conditions
- Autoantibodies
Interventions
- OTHER
-
No intervention
No intervention.
Sponsors & Collaborators
- lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-02-09
- Primary Completion
- 2038-12-31
- Completion
- 2038-12-31
Countries
- Sweden
Study Locations
More Related Trials
-
A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02
NCT00583362 ·Status: COMPLETED ·Phase: PHASE2
-
Comparative Autoantibody and Immunologic Cell Marker Study
NCT02422875 ·Status: ENROLLING_BY_INVITATION
-
Clinical Performance of BioCLIA Ro60
NCT03204448 ·Status: WITHDRAWN
-
Identification of Correlations Between Reaction to Biotine and Autoimmune Diseases
NCT01934764 ·Status: UNKNOWN
-
Catalytic Antibodies and Lupus in Martinique
NCT01157468 ·Status: COMPLETED
-
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
NCT05000216 ·Status: TERMINATED ·Phase: PHASE2
-
T and B Cell Responses in Autoimmune Diseases
NCT01947036 ·Status: TERMINATED
-
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
NCT00724867 ·Status: COMPLETED ·Phase: PHASE3
-
Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
NCT06417398 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Autoantibodies in Treatment with Immune Checkpoint Inhibitors (AUTENTIC)
NCT03868046 ·Status: COMPLETED
-
A Model About the Response of Belimumab in SLE
NCT04893161 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Lymphocyte Sub-populations and Auto Immune Diseases
NCT03901664 ·Status: COMPLETED
-
Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease
NCT00660881 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus
NCT02725515 ·Status: COMPLETED ·Phase: PHASE2
-
Analysis of B Cells From Autoimmune Individuals
NCT02747277 ·Status: COMPLETED
-
An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT04810754 ·Status: UNKNOWN ·Phase: PHASE2
-
Clinical Autoinflammatory Disease Cohort
NCT07126145 ·Status: NOT_YET_RECRUITING
-
Autotaxin as Abiomarker in Systemic Lupus Erythematosus Patients
NCT06063668 ·Status: NOT_YET_RECRUITING
-
Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases
NCT05251415 ·Status: RECRUITING
-
Biomarkers in Autoimmune Diseases, Vasculitis and Auto Inflammatory Diseases
NCT05383339 ·Status: RECRUITING
-
Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
NCT06581562 ·Status: RECRUITING ·Phase: PHASE1
-
Evaluation of Patients With Systemic Sclerosis Without Specific or Associated Autoantibodies
NCT06412614 ·Status: NOT_YET_RECRUITING
-
A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia
NCT01345708 ·Status: COMPLETED ·Phase: PHASE2
-
INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use
NCT06314282 ·Status: RECRUITING
-
Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE
NCT01702038 ·Status: WITHDRAWN ·Phase: PHASE2